Passage Bio, Inc. announced that its Board of Directors approved a 1-for-20 reverse stock split of the company’s outstanding common stock, effective July 14, 2025.
The primary purpose of the reverse stock split is to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share. The action was approved by Passage Bio’s stockholders at the 2025 annual meeting held on May 28, 2025.
The reverse stock split will reduce the number of outstanding common shares from approximately 62,405,898 to approximately 3,120,295. Proportionate adjustments will be made to equity awards and incentive plans, with no change to authorized shares or par value per share.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.